Ignite Creation Date:
2025-12-24 @ 2:01 PM
Ignite Modification Date:
2026-02-07 @ 11:59 PM
Study NCT ID:
NCT00876395
Status:
COMPLETED
Last Update Posted:
2018-12-19
First Post:
2009-04-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Breast Cancer | View |
| None | HER2+ | View |
| None | mTOR | View |
| None | everolimus | View |
| None | RAD001 | View |
| None | first line | View |
| None | metastatic | View |
| None | locally advanced | View |
| None | Trastuzumab | View |
| None | Paclitaxel | View |
| None | First Line Therapy | View |
| None | HER2 Positive | View |
| None | Metastatic Breast Cancer | View |